Trial Profile

Multi-institutional observational study for the efficacy and safety of Carfilzomib for multiple myeloma in Kyoto Clinical Hematology Study Group (KOTOSG)

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms KOTOSG-CFZ

Most Recent Events

01 Jul 2022 Results of ad hoc analysis of CFZ-related CVAEs in patients with RRMM, published in the Leukemia and Lymphoma
06 Jun 2022 Status changed from active, no longer recruiting to completed.
22 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com